The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review

被引:20
|
作者
Harris, Rebecca C. [1 ]
Grandjean, Louis [2 ]
Martin, Laura J. [3 ]
Miller, Alexander J. P. [1 ]
Nkang, Joseph-Egre N. [1 ]
Allen, Victoria [4 ]
Khan, Mishal S. [1 ,5 ]
Fielding, Katherine [1 ,6 ]
Moore, David A. J. [1 ]
机构
[1] Univ London London Sch Hyg & Trop Med, TB Ctr, Keppel St, London WC1E 7HT, England
[2] UCL, Inst Child Hlth, Dept Infect Immunol & Rheumatol, Guilford St, London WC1E 6BT, England
[3] Royal Brompton & Harefield NHS Fdn Trust, Sydney St, London SW3 6NP, England
[4] Chelsea & Westminster Hosp, 369 Fulham Rd, London SW10 9NH, England
[5] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 119077, Singapore
[6] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa
关键词
Multi-drug resistant; Extensively drug resistant; Tuberculosis; Treatment delay; Systematic review; COMMUNITY-BASED TREATMENT; MDR-TB; CLINICAL-FEATURES; TREATMENT SUCCESS; CHILDREN; HIV; LIMA; KHAYELITSHA; PREDICTORS; MORTALITY;
D O I
10.1186/s12879-016-1524-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Globally it is estimated that 480 000 people developed multidrug-resistant tuberculosis (MDR-TB) in 2014 and 190 000 people died from the disease. Successful treatment outcomes are achieved in only 50 % of patients with MDR-TB, compared to 86 % for drug susceptible disease. It is widely held that delay in time to initiation of treatment for MDR-TB is an important predictor of treatment outcome. The objective of this review was to assess the existing evidence on the outcomes of multidrug-and extensively drug-resistant tuberculosis patients treated early (<= 4 weeks) versus late (> 4 weeks) after diagnosis of drug resistance. Methods: Eight sources providing access to 17 globally representative electronic health care databases, indexes, sources of evidence-based reviews and grey literature were searched using terms incorporating time to treatment and MDR-TB. Two-stage sifting in duplicate was employed to assess studies against pre-specified inclusion and exclusion criteria. Only those articles reporting WHO-defined treatment outcomes were considered for inclusion. Articles reporting on fewer than 10 patients, published before 1990, or without a comparison of outcomes in patient groups experiencing different delays to treatment initiation were excluded. Results: The initial search yielded 1978 references, of which 1475 unique references remained after removal of duplicates and 28 articles published pre-1990. After title and abstract sifting, 64 papers underwent full text review. None of these articles fulfilled the criteria for inclusion in the review. Conclusions: Whilst there is an inherent logic in the theory that treatment delay will lead to poorer treatment outcomes, no published evidence was identified in this systematic review to support this hypothesis. Reports of programmatic changes leading to reductions in treatment delay exist in the literature, but attribution of differences in outcomes specifically to treatment delay is confounded by other contemporaneous changes. Further primary research on this question is not considered a high priority use of limited resources, though where data are available, improved reporting of outcomes by time to treatment should be encouraged.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review
    Fraser, A
    Paul, M
    Attamna, A
    Leibovici, L
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2006, 10 (01) : 19 - 23
  • [22] Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China
    Chen, Yong
    Yuan, Zhengan
    Shen, Xin
    Wu, Jie
    Wu, Zheyuan
    Xu, Biao
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (04)
  • [23] Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
    Aibana, Omowunmi
    Bachmaha, Mariya
    Krasiuk, Viatcheslav
    Rybak, Natasha
    Flanigan, Timothy P.
    Petrenko, Vasyl
    Murray, Megan B.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [24] Treatment outcomes of multidrug-resistant tuberculosis in Switzerland
    Helbling, Peter
    Altpeter, Ekkehardt
    Egger, Jean-Marie
    Zellweger, Jean-Pierre
    SWISS MEDICAL WEEKLY, 2014, 144
  • [25] Effectiveness and safety of tuberculosis preventive treatment for contacts of patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis
    Zhou, Guozhong
    Luo, Shiqi
    He, Jian
    Chen, Nan
    Zhang, Yu
    Cai, Shunli
    Guo, Xin
    Chen, Hongbo
    Song, Chao
    CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (02) : 189 - 196
  • [26] Clofazimine as a Treatment for Multidrug-Resistant Tuberculosis: A Review
    Nugraha, Rhea Veda
    Yunivita, Vycke
    Santoso, Prayudi
    Aarnoutse, Rob E.
    Ruslami, Rovina
    SCIENTIA PHARMACEUTICA, 2021, 89 (02)
  • [27] The Effect of Smoking on Treatment Outcome of Multidrug-Resistant Tuberculosis
    Pazarli, Pinar
    Duman, Dildar Yetis
    Mocin, Ozlem Yazicioglu
    Karagoz, Turan
    TURKISH THORACIC JOURNAL, 2013, 14 (03) : 93 - 97
  • [28] The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review and meta-analysis
    Wagnew, Fasil
    Alene, Kefyalew Addis
    Kelly, Matthew
    Gray, Darren
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 127 : 93 - 105
  • [29] Barriers faced by patients in the diagnosis of multidrug-resistant tuberculosis in Brazil
    Bhering, Marcela
    Dalcolmo, Margareth
    Sarubbi Junior, Vicente
    Kritski, Afranio
    REVISTA DE SAUDE PUBLICA, 2022, 56
  • [30] Pulmonary resection for patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
    Xu, Hong-Bin
    Jiang, Rui-Hua
    Li, Ling
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (08) : 1687 - 1695